GlassScriptPhysician profile
Bilal Hasan
NPI 1073001921
$3,156.14
in general payments reported to CMS, 2019-2025
23 companies · $2,302 in 2025
The $2,302 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $854 · 2025: $2,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.16 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.42 | 2024-2025 | |
| Amgen INC. | $555.43 | 2024-2025 | Krystexxa, Otezla, Evenity |
| Janssen Biotech, INC. | $497.72 | 2024-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $265.01 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $182.06 | 2024-2025 | Acthar |
| Pfizer INC. | $122.07 | 2024-2025 | |
| Bioventus LLC | $109.59 | 2024-2025 | Gelsyn-3 |
| Organon LLC | $109.42 | 2025 | Renflexis, Hadlima, Nexplanon |
| Astrazeneca Pharmaceuticals LP | $102.55 | 2025 | Saphnelo |
| Radius Health, INC. | $96.77 | 2025 | Tymlos |
| Glaxosmithkline, LLC. | $78.11 | 2025 | Benlysta |
| Fresenius Kabi USA, LLC | $66.29 | 2024-2025 | Idacio |
| Octapharma USA, INC. | $65.50 | 2024 | Octagam Immune Globulin (Human) |
| Ucb, INC. | $53.67 | 2024-2025 | Bimzelx |
| Invivyd INC | $51.87 | 2025 | Pemgarda |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.51 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $30.15 | 2025 | Hyqvia |
| Sandoz INC. | $27.41 | 2025 | Jubbonti |
| Aurinia Pharma U.S., INC. | $23.76 | 2024 | Lupkynis |
| Genzyme Corporation | $22.73 | 2025 | |
| Lundbeck LLC | $18.83 | 2024 | Vyepti |
| Lilly USA, LLC | $18.23 | 2025 | Kisunla |
| Genentech USA, INC. | $15.04 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.